Evidence map›Paper›PMID 39202273›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Effects of Curcumin and Estrogen Receptor Alpha in Luminal Breast Cancer Cells.

Lorena Palacios-Navarro, Leodan A Crispin, Juan P Muñoz, Gloria M Calaf

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lorena Palacios-NavarroInstituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile.ORCID 0009-0000-7677-8140
Leodan A CrispinInstituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile.ORCID 0000-0002-4026-2641
Juan P MuñozInstituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile.
Gloria M CalafInstituto de Alta Investigación, Universidad de Tarapacá, Arica 1000000, Chile.ORCID 0000-0003-3542-296X

Funding

Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT/ANID) FONDECYT 1200656 (G.M.C)Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT/ANID) FONDECYT 1231537 (G.M.C)Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT/ANID) Postdoctoral Grant 3190744 (J.P.M)
6 · The paper itself

Abstract

This work examined the potential benefit of curcumin in breast cancer patients as a supplementary drug in ER-positive cancers. The results indicated that in the MCF-7 human breast cancer cell line, E2 and curcumin decreased cell proliferation and the colony-forming capacity and down-regulated protein expression as well as important molecules associated with cell proliferation, such as PCNA and estrogen receptor alpha; genes associated with the epithelial-mesenchymal transition, such as β-catenin, Vimentin, and E-cadherin; and molecules associated with apoptosis. Clinical studies in bioinformatics have indicated a positive correlation between

Indexed as

17ß-estradiolantiestrogensbreast cancercancer therapycurcuminestrogen receptor alphaestrogens

Identifiers

PMID39202273
PMCPMC11353822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.